Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSH6 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
MSH6 mutation	Colorectal Cancer	MSH6 mutation	Colorectal Cancer	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3
MSH6 mutation	Triple Negative Breast Cancer	MSH6 mutation	Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
MSH6 mutation	Rectal Cancer	MSH6 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH6 mutation	Endometrial Cancer	MSH6 mutation	Endometrial Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
MSH6 mutation	Breast Cancer	MSH6 mutation	Breast Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH6 mutation	Germ Cell Tumors	MSH6 mutation	Germ Cell Tumors	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4